Peptide Initiative

Peptide profile · Growth Hormone

Capromorelin

An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.

Moderate human trialsNot approved for human use
About 1.2 hours in dogsHalf-life (ENTYCE label)
44% oral in dogs and 65% in rats; no human figure published on this pageBioavailability
505.6Molecular weight, g/mol

Molecular formula

C28H35N5O4

CAS number
193273-66-4
PubChem
216208
Developed · 2001
Pfizer Global Research and Development (Carpino et al.), Pfizer Inc.

Amino acid sequence

Sequence not publicly available or proprietary

GH & IGF-1 StimulationPotent, dose-dependent growth hormone and IGF-1 elevation through oral ghrelin receptor agonism, supporting anabolic and metabolic pathways

8.8

Physical FunctionIn the pooled treatment groups of a phase 2 trial in older adults, tandem walk improved by 0.9 seconds at 6 months and stair climb improved by 12 months, versus placebo.

8.2

Oral ConvenienceNo injections or reconstitution needed — simple oral capsule with proven bioavailability and predictable pharmacokinetics

9.2

Ratings out of 10.

3 – 10mg

Every documented dose level

PhaseDoseFrequency
Initial weeks3 mgTwice daily
Ongoing10 mgOnce daily at bedtime
Up to 12 months in the trial10 mgTwice daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for stimulating growth hormone production in elderly adults & supporting appetite and weight gain in wasting conditions

Best for

  • Age-Related Muscle Wasting

    Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.

  • Appetite Stimulation

    As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.

  • Growth Hormone Research

    One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.

Consider alternatives if

Oral GH secretagogue with more human dataMK-677 (Ibutamoren)Tabimorelin
Injectable GH-releasing peptidesGHRP-6IpamorelinGHRH (1-29) / Sermorelin

Do not use if

  • Active or history of malignancy (GH/IGF-1 pathway may promote tumor growth)
  • Uncontrolled diabetes or significant insulin resistance
  • Pregnancy or breastfeeding (no human safety data)

Use with caution if

  • Pre-diabetic or borderline glucose tolerance (monitor blood sugar closely)
  • Taking medications that affect appetite or metabolism
  • History of pituitary disorders or prior pituitary surgery
  • Elderly patients with cardiovascular conditions

Not sure?

Compare Capromorelin with similar peptides to find the best fit for your goals.

Route

Not applicable — Capromorelin is administered orally only

Best sites

  • Not applicable (oral administration)

The Capromorelin dosing protocol covers how it is taken.

2 common side effects · 1 serious

Emergency signs first, then what this page and MedlinePlus say.

Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants.

Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.

Human safety data comes primarily from a single Phase 2 trial (White et al., 2009) with 395 elderly subjects. Extensive veterinary safety data exists from FDA-approved products Entyce (dogs) and Elura (cats).


Common side effects · experienced by some users

Appetite stimulation

Increased hunger and food intake. This is the intended mechanism for veterinary use but may be unwanted for some human users. Appetite increase is typically strongest in the first 2-3 weeks, then may stabilize or gradually decrease.

Management
If weight gain is undesired, monitor caloric intake closely and maintain consistent meal timing. Increase protein consumption to support lean muscle development. Consider timing dosing away from meal prep or dining triggers. Drink more water to help with satiety.

Fluid retention and weight gain

Mild to moderate water retention and lean weight gain due to GH effects. May cause temporary increase in body weight, typically 2-5 lbs over a 4-6 week cycle. Most weight gained is lean mass rather than fat, though some water retention is expected.

Management
Monitor body composition rather than just scale weight. Reduce sodium intake slightly to minimize water retention. Maintain adequate hydration. Most fluid retention resolves within 1-2 weeks post-cycle. Use compression garments if peripheral edema is bothersome.

Serious side effects

Hyperglycemia

GH is diabetogenic and can raise blood glucose levels, particularly problematic in those with diabetes or metabolic disorders. Capromorelin can increase fasting glucose by 5-15 mg/dL in some users. Insulin resistance may develop, though this is usually reversible post-cycle.

Management
Check fasting glucose and HbA1c before starting. Monitor blood glucose weekly during the cycle—especially if pre-diabetic or overweight. Increase aerobic exercise to 150+ min/week to improve insulin sensitivity. Reduce refined carbohydrates and simple sugars. If glucose rises above 110 mg/dL fasting, reduce dose or discontinue. Consult healthcare provider before use if diabetic.

Less commonJoint and muscle achesFatigue or lethargyPeripheral edema (swelling)

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe allergic reaction (rash, swelling, difficulty breathing)
  • Significant blood glucose elevation that doesn't normalize
  • Persistent nausea, vomiting, or GI distress not relieved by dose adjustment
  • Unwanted excessive appetite or weight gain
  • Development of peripheral edema or fluid retention

Always consult a healthcare professional before starting or stopping any peptide or research compound. This information is for educational purposes only.


With other peptides

  • SafeGHRH analogs (Sermorelin, Tesamorelin) — Synergistic GH release — GHRH stimulates via a different receptor pathway
  • CautionOther ghrelin agonists (MK-677, GHRP-6) — Redundant mechanism — may not add benefit and could increase side effects

With medications

  • CautionInsulin / Oral hypoglycemics — Capromorelin may elevate blood glucose; monitor closely and adjust diabetes medications as needed
  • CautionCorticosteroids — Both affect glucose metabolism; increased hyperglycemia risk when combined

With supplements

  • SafeArginine / Ornithine — May modestly enhance GH release when combined with ghrelin agonists
  • SafeMelatonin — Some evidence melatonin supports GH secretion during sleep; generally safe to combine

Moderate human trials · first signs 24-48 hours

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Not approved for human use

FDA-approved for veterinary use only: ENTYCE (appetite stimulation in dogs, 2016) and ELURA (weight loss in cats with chronic kidney disease, 2020); both labels state "not for use in humans".

Onset of effects

Moderate

(1-2 weeks)


How it works

Capromorelin is a small molecule that mimics ghrelin, the hunger hormone.

It acts on the ghrelin receptor in the hypothalamus to stimulate appetite, and in the pituitary to release growth hormone. In older adults it raised IGF-1 and increased lean body mass.

The deeper mechanism

Capromorelin is a selective ghrelin receptor agonist: it binds the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus, stimulating appetite, and in the pituitary, increasing growth hormone secretion. It binds human GHS-R1a with a Ki of 7 nM.

It is metabolized mainly by CYP3A4 and CYP3A5. In dogs it peaks within about 50 minutes and has a half-life of about 1.2 hours. In older adults, every dose raised peak nocturnal GH (most with the least frequent dosing) and produced a sustained, dose-related rise in IGF-1.


What to expect

  1. 24-48 hours

    What you might notice

    • GH elevation peaks within the first day
    • Initial appetite stimulation may begin

    What's normal

    • Initial response to Capromorelin is beginning at the cellular level
    • Different individuals experience Capromorelin's onset at different rates
    • Transient systemic effects from initial Capromorelin exposure are common

    What's next

    • Maintain consistent Capromorelin administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. 1-2 weeks

    What you might notice

    • IGF-1 levels rise progressively
    • Users may notice increased appetite and energy
    • Physical performance improvements become apparent

    What's normal

    • Capromorelin has achieved stable, long-term homeostatic integration
    • Sustained efficacy of Capromorelin remains consistent
    • Chronic Capromorelin effects remain stable and predictable

    What's next

    • Maintain your established Capromorelin protocol for sustained benefits
    • Continue periodic monitoring to confirm Capromorelin efficacy
    • Review comprehensive Capromorelin response with your provider
  3. 4-6 weeks

    What you might notice

    • In the human trial, lean mass (+1.4 kg) and tandem walk changes were measured at 6 months, not at 4–6 weeks
    • No study has defined an optimal cycle length; the human trial dosed continuously for up to 12 months

    What's normal

    • Full therapeutic effects of Capromorelin are well-characterized at this point
    • Maintenance of Capromorelin's therapeutic effects is typical
    • Tolerance patterns with Capromorelin are generally stable over months

    What's next

    • Comprehensive assessment of Capromorelin efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Hormonal

  • Elevated IGF-1 on blood work
  • Increased GH levels measured 30-90 minutes post-dose

Signs it's working

Physical

  • Improved appetite and food intake
  • Better exercise recovery
  • Enhanced muscle tone or strength

Not seeing results?

Common reasons

  • Dose may be too low — Phase 2 data showed 10-30 mg was needed for meaningful effects
  • Not enough time — GH/IGF-1 elevation builds gradually over 1-2 weeks of consistent dosing
  • Taking with high-fat meals may alter absorption timing
  • Individual variation in ghrelin receptor sensitivity
  • Concurrent medications that affect GH axis (e.g., somatostatin analogs) may blunt response

Is capromorelin FDA-approved for human use?

No. Capromorelin is FDA-approved only for veterinary use: Entyce for dogs (2016) to stimulate appetite, and Elura for cats (2020) to manage weight in chronic kidney disease. Human Phase 2 clinical trials were conducted in elderly subjects showing safety and efficacy, but development for human use was not pursued to FDA approval. It remains a research compound for human applications.

How does capromorelin compare to MK-677 (ibutamoren)?

Both are oral ghrelin agonists that stimulate GH and IGF-1. MK-677 has more human clinical data and is more widely available in research settings. Capromorelin was developed earlier (1999-2001) and has stronger veterinary evidence. Capromorelin has a shorter plasma half-life (1-2.4 hours) compared to MK-677's longer half-life (~24 hours), though both produce sustained GH stimulation. MK-677 may cause more hunger, while capromorelin's appetite effects are more moderate.

Why was capromorelin developed for veterinary use but not pursued for humans?

Capromorelin was developed by Pfizer and showed promise in human Phase 2 trials, but pharmaceutical development is driven by market opportunity and competitive landscape. By the time human efficacy was confirmed, the anti-aging market landscape had shifted. Aratana Therapeutics acquired the veterinary rights and successfully developed it for pet health, which has a clearer regulatory pathway and proven commercial success.

Is capromorelin safe for elderly individuals?

The phase 2 trial randomized 395 adults aged 65–84 to 10 mg three times a week, 3 mg twice a day, 10 mg each night, 10 mg twice a day, or placebo. At 6 months, the pooled treatment groups gained 1.4 kg of body weight and 1.4 kg of lean mass and improved tandem walk; stair climb improved by 12 months. Adverse events included fatigue, insomnia and small rises in fasting glucose, HbA1c and insulin resistance, so glucose should be monitored.

What is the mechanism of action?

Capromorelin is a peptidomimetic ghrelin receptor agonist. It binds to and activates the GHS-R1a (growth hormone secretagogue receptor 1a) on hypothalamic neurons, triggering the release of growth hormone-releasing hormone (GHRH). This stimulates the anterior pituitary to secrete growth hormone, which then stimulates liver IGF-1 production. Additionally, capromorelin activates appetite centers in the hypothalamus, explaining its appetite-stimulating effects used in veterinary practice.

How long is the typical cycle, and is post-cycle therapy needed?

The only human trial planned 2 years of daily dosing; it stopped early, with 315 people completing 6 months and 284 completing 12 months. It did not use short cycles, and no study has tested cycling or post-cycle therapy. GH and IGF-1 effects depend on continued dosing.

Can women use capromorelin?

Capromorelin is not approved for human use, and pregnant and lactating women should avoid it. For non-pregnant women interested in GH stimulation for muscle, bone, or anti-aging purposes, capromorelin theoretically works similarly in both sexes (GH effects are largely sex-neutral). However, given lack of human approval and female-specific safety data, medical supervision would be essential.

What is the oral bioavailability, and does food affect absorption?

Oral bioavailability was 44% in dogs and 65% in rats; no human figure is published here. Food matters: in cats, feeding lowered peak levels by 55% and total exposure by 43%.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Capromorelin, on one page.

Capromorelin dosing protocol

Medical disclaimer

Capromorelin is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

3 – 10 mg Twice daily or once daily at bedtime · onset 1-2 weeks
Open the Capromorelin calculatorCapromorelin calculator